Related Experiment Video
Updated: Dec 9, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
[Intermediate-risk pulmonary embolism - Update on risk stratification and clinical management]
Sophie Greutert1, Nahomy Mozuasadila1, Amandine Berner2
1Service de médecine interne et des soins intensifs, Hôpital de Nyon, GHOL, 1260 Nyon.
Abstract:
Intermediate-risk pulmonary embolism (PE) is usually defined as PE associated with right ventricular dysfunction (echocardiographic, radiological and/or biological) without hemodynamic instability. It is associated with significant mortality, and its management is challenging for the clinician due to its variable clinical presentation. In its recent recommendations, the European Society of Cardiology proposes to differentiate high intermediate risk from low intermediate risk, based on clinical, biological and radiological criteria. The management strategy differs for these two categories, particularly about the need for monitored surveillance. Beyond therapeutic anticoagulation, which remains the first-line treatment in intermediate-risk PE, other therapeutic modalities can be considered, and will be discussed.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Venous Thrombosis III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

